Voltron Therapeutics Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $3.51M

  • Investors
  • 3

Voltron Therapeutics General Information

Description

Developer of a vaccine platform designed to treat cancer and infectious diseases. The company develops a proprietary self-assembling vaccine technology that targets peptides for cell-mediated responses to combat infectious diseases, such as COVID-19 and specific forms of cancers, enabling researchers to develop treatments for cancer and infectious diseases.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 12 East 49th Street
  • 11th Floor
  • New York, NY 10017
  • United States
+1 (646)
Primary Industry
Drug Discovery
Vertical(s)
Corporate Office
  • 12 East 49th Street
  • 11th Floor
  • New York, NY 10017
  • United States
+1 (646)

Voltron Therapeutics Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Voltron Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC 09-Nov-2023 $3.51M Completed Pre-Clinical Trials
3. Grant 17-Aug-2023 Completed Pre-Clinical Trials
2. Early Stage VC 31-Aug-2021 $5.85M $9.4M Completed Pre-Clinical Trials
1. Early Stage VC (Series A) 09-Jun-2020 $3.5M $3.5M Completed Pre-Clinical Trials
To view Voltron Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Voltron Therapeutics Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds
United States Department of War Government
Lucius Partners Corporation Minority
Laidlaw & Company Investment Bank Minority
To view Voltron Therapeutics’s complete investors history, request access »

Voltron Therapeutics Investments (1)

Voltron Therapeutics’s most recent deal was a Joint Venture with HaloVax. The deal was made on 23-Mar-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
HaloVax 23-Mar-2020 Joint Venture Biotechnology
To view Voltron Therapeutics’s complete investments history, request access »

Voltron Therapeutics FAQs

  • When was Voltron Therapeutics founded?

    Voltron Therapeutics was founded in 2017.

  • Where is Voltron Therapeutics headquartered?

    Voltron Therapeutics is headquartered in New York, NY.

  • What industry is Voltron Therapeutics in?

    Voltron Therapeutics’s primary industry is Drug Discovery.

  • Is Voltron Therapeutics a private or public company?

    Voltron Therapeutics is a Private company.

  • What is Voltron Therapeutics’s current revenue?

    The current revenue for Voltron Therapeutics is .

  • How much funding has Voltron Therapeutics raised over time?

    Voltron Therapeutics has raised $12.9M.

  • Who are Voltron Therapeutics’s investors?

    United States Department of War, Lucius Partners, and Laidlaw & Company have invested in Voltron Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process